JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Irino, Tamotsu ^a,b   Uemura, Munehiro ^c   Yamane, Humitsugu ^d   Umemura, Shigeto ^a   Utsumi, Takahiko ^a   Kakazu, Naoki ^d   Shirakawa, Taku ^b   Ito, Mitsuhiro ^b   Suzuki, Takayo ^a   Kinoshita, Kazuo ^c  

^a Shiga Medical Center for Adults   (Japan)

^b KOBE UNIVERSITY   (Japan)

^c Shiga Medical Center Research Institute   (Japan)

^d SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GENOMIC DNA; JANUS KINASE 2; MESSENGER RNA; PROTEIN PU.1; SMALL INTERFERING RNA; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; JAK2 PROTEIN, HUMAN; ONCOPROTEIN; PROTO ONCOGENE PROTEIN SPI 1; PROTO-ONCOGENE PROTEIN SPI-1; SOCS1 PROTEIN, HUMAN; SOCS3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING; TRANSACTIVATOR PROTEIN;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FREQUENCY; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; JANUS KINASE 2 GENE; MALE; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE NEOPLASM; ONCOGENE; PROTEIN FUNCTION; PROTEIN TARGETING; PU.1 GENE; REAL TIME POLYMERASE CHAIN REACTION; RNA TRANSPORT; SIGNAL TRANSDUCER AND ACTIVATOR TRANSCRIPTION GENE; SIGNAL TRANSDUCTION; SPLEEN FOCUS FORMING VIRUS PROVIRAL INTEGRATION ONCOGENE 1 GENE; SUPPRESSOR OF CYTOKINE SIGNALLING 3 GENE; UPREGULATION; WESTERN BLOTTING; WILD TYPE; AMINO ACID SUBSTITUTION; BLOOD; BONE MARROW CANCER; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; MYELOPROLIFERATIVE DISORDER;

AGED; AMINO ACID SUBSTITUTION; BONE MARROW NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANS-ACTIVATORS; UP-REGULATION;

EID: 79960608530     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022148     Document Type: Article

References (29)

1. Tefferi A, Vardiman JW, (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22: 14-22.
2. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, et al. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106: 2162-2168.
3. Levy DE, Darnell JE Jr, (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662.
4. Schindler C, Levy DE, Decker T, (2007) JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282: 20059-20063.
5. Li WX, (2008) Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol 18: 545-551.
6. Gupta P, Gurudutta GU, Saluja D, Tripathi RP, (2009) PU.1 and partners: regulation of haematopoietic stem cell fate in normal and malignant haematopoiesis. J Cell Mol Med 13: 4349-4363.
7. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061.
8. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, et al. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356: 459-468.
9. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, et al. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108: 3472-3476.
10. Isomaki P, Alanara T, Isohanni P, Lagerstedt A, Korpela M, et al. (2007) The expression of SOCS is altered in rheumatoid arthritis. Rheumatology 46: 1538-1546.
11. Ma AC, Ward AC, Liang R, Leung AY, (2007) The role of jak2a in zebrafish hematopoiesis. Blood 110: 1824-1830.
12. Quentmeier H, MacLeod RA, Zaborski M, Drexler HG, (2006) JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 20: 471-476.
13. Ilaria RL Jr, Van Etten RA, (1996) P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271: 31704-31710.
14. Coppo P, Flamant S, De Mas V, Jarrier P, Guillier M, et al. (2006) BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 134: 171-179.
15. Croker BA, Kiu H, Nicholson SE, (2008) SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 19: 414-422.
16. Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, et al. (2007) The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 109: 4924-4929.
17. Elliott J, Suessmuth Y, Scott LM, Nahlik K, McMullin MF, et al. (2009) SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases. Haematologica 94: 576-580.
18. Fisher RC, Slayton WB, Chien C, Guthrie SM, Bray C, et al. (2004) PU.1 supports proliferation of immature erythroid progenitors. Leuk Res 28: 83-89.
19. Aittomaki S, Pesu M, Groner B, Janne OA, Palvimo JJ, et al. (2000) Cooperation among Stat1, glucocorticoid receptor, and PU.1 in transcriptional activation of the high-affinity Fc gamma receptor I in monocytes. J Immunol 164: 5689-5697.
20. Moreau-Gachelin F, Wendling F, Molina T, Denis N, Titeux M, et al. (1996) Spi-1/PU.1 transgenic mice develop multistep erythroleukemias. Mol Cell Biol 16: 2453-2463.
21. Matushansky I, Radparvar F, Skoultchi AI, (2003) CDK6 blocks differentiation: coupling cell proliferation to the block to differentiation in leukemic cells. Oncogene 22: 4143-4149.
22. Pui CH, Relling MV, Downing JR, (2004) Acute lymphoblastic leukemia. N Engl J Med 350: 1535-1548.
23. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM, (2008) Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8: 497-511.
24. Janknecht R, (2005) EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene 363: 1-14.
25. Sharrocks AD, (2001) The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2: 827-837.
26. Schroeder T, Kohlhof H, Rieber N, Just U, (2003) Notch signaling induces multilineage myeloid differentiation and up-regulates PU.1 expression. J Immunol 170: 5538-5548.
27. Berclaz PY, Carey B, Fillipi MD, Wernke-Dollries K, Geraci N, et al. (2007) GM-CSF regulates a PU.1-dependent transcriptional program determining the pulmonary response to LPS. Am J Respir Cell Mol Biol 36: 114-121.
28. Albajar M, Gutierrez P, Richard C, Rosa-Garrido M, Gomez-Casares MT, et al. (2008) PU.1 expression is restored upon treatment of chronic myeloid leukemia patients. Cancer Lett 270: 328-336.
29. Morceau F, Buck I, Dicato M, Diederich M, (2008) Radicicol-mediated inhibition of Bcr-Abl in K562 cells induced p38-MAPK dependent erythroid differentiation and PU.1 down-regulation. Biofactors 34: 313-329.